Printer Friendly

MolecularMD, Novartis team up on companion diagnostic test development.

M2 PHARMA-February 19, 2014-MolecularMD, Novartis team up on companion diagnostic test development

(C)2014 M2 COMMUNICATIONS

19 February 2014 - US molecular diagnostics company MolecularMD Corp said Wednesday it had partnered with Novartis Pharmaceuticals Corp, the US unit of Swiss Novartis AG (VTX:NOVN), for the development of a companion diagnostic test to detect Ph+ chronic myelogenous leukemia (CML) patients who have achieved durable minimal residual disease (MRD) with Tasigna (nilotinib).

MolecularMD will validate an in-vitro companion diagnostic test intended to monitor CML patients during treatment-free remission. The assay is based on highly sensitive quantitative real-time PCR (RT-qPCR) identification of BCR-ABL mRNA transcripts and the endogenous ABL mRNA transcript control in peripheral blood specimens from CML patients.

Novartis is currently carrying out an international clinical study programme to find if nilotinib therapy can be safely suspended with no recurrence of CML in selected patients who achieved MR4.5 (BCR-ABL less than or equal to 0.0032% IS) on nilotinib therapy. MolecularMD is engaged in the clinical trial assay (CTA) quantifying of BCR-ABL mRNA transcript levels in the study.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 19, 2014
Words:188
Previous Article:NeoGenomics' test volume rises 27.8% Y/Y in Q4 2013.
Next Article:Ampio Pharmaceuticals Inc concludes dosing in second pivotal clinical trial of Ampion for OAK; BLA to be filed later this year.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters